ERBB2 and breast carcinoma: For example, a Phase I clinical trial (NCT02683083) evaluated an 131I-labeled anti-HER2 nanobody in breast cancer patients, and nanobody-based diagnostics are being developed for non-invasive cancer diagnosis; they offer advantages such as fast tumor penetration and a short half-life, allowing for same-day molecular imaging with a low radiation load [73,74].